ClinVar Miner

Submissions for variant NM_000465.4(BARD1):c.1348_1349delinsCAT (p.Asn450fs)

dbSNP: rs1553619713
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV001010996 SCV001171272 pathogenic Hereditary cancer-predisposing syndrome 2021-04-12 criteria provided, single submitter clinical testing The c.1348_1349delAAinsCAT pathogenic mutation, located in coding exon 5 of the BARD1 gene, results from the deletion of two nucleotides and insertion of 3 nucleotides causing a translational frameshift with a predicted alternate stop codon (p.N450Hfs*4). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Color Diagnostics, LLC DBA Color Health RCV001010996 SCV001342051 pathogenic Hereditary cancer-predisposing syndrome 2019-08-08 criteria provided, single submitter clinical testing This variant replaces 2 nucleotides in exon 5 of the BARD1 gene with 3 new nucleotides, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. Computational splicing tools suggest that this variant may not impact RNA splicing. To our knowledge, functional assays have not been performed for this variant nor has this variant been reported in individuals affected with hereditary cancer in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BARD1 function is a known mechanism of disease. Based on available evidence, this variant is classified as Pathogenic.
Myriad Genetics, Inc. RCV003336099 SCV004044375 pathogenic Familial cancer of breast 2023-05-23 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.
Baylor Genetics RCV003336099 SCV004217321 likely pathogenic Familial cancer of breast 2022-09-01 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.